Welcome to our dedicated page for Abbott Labs SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abbott Laboratories SEC filings document an Illinois healthcare company with common shares listed under ABT and operations in diagnostics, medical devices, nutritionals and branded generic medicines. The filings include Form 8-K reports on operating results, non-GAAP financial measures, material agreements, acquisition-related events, debt financing and amendments to corporate governance documents.
Abbott's proxy and event filings cover shareholder voting matters, board and bylaw governance, executive compensation, capital-structure disclosures and clinical or regulatory disclosures. The filing record also documents the completed Exact Sciences acquisition and the addition of cancer diagnostics to Abbott's broader diagnostic portfolio.
Cushman Elizabeth C. reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories executive Elizabeth C. Cushman, EVP, GC and Secretary, reported equity awards on February 24, 2026. She received an employee stock option for 61,964 options under the Abbott 2017 Incentive Stock Program, exercisable in three annual installments starting in 2027. She was also granted 15,031 performance-based restricted shares with a three-year term, with no more than one-third vesting in any year, contingent on Abbott reaching a minimum return-on-equity target and allowing shares to be withheld for taxes.
ABBOTT LABORATORIES executive Philip P. Boudreau, EVP and CFO, reported equity awards. On February 24, 2026, he acquired an employee stock option for 115,413 shares with no exercise price shown here, granted under the Abbott Laboratories 2017 Incentive Stock Program and scheduled to become exercisable in three equal annual installments beginning February 24, 2027.
On the same date, he also received a performance-based restricted stock award of 27,997 common shares without par value, with a three‑year term and no more than one‑third vesting in any year, contingent on Abbott reaching a minimum return on equity target and allowing share withholding for taxes. Following these awards, he directly owned 78,613 common shares and indirectly held 366 shares through an Abbott Laboratories Stock Retirement Trust as of February 24, 2026.
Abbott Laboratories entered into a pricing agreement to issue and sell $20,000,000,000 aggregate principal amount of senior notes across eight tranches, including Floating Rate Notes due 2029 and Fixed Rate Notes with coupons from 3.700% to 5.600% maturing between 2029 and 2066.
The notes were priced through a syndicate led by major underwriters and offered under Abbott’s effective shelf registration statement via a prospectus and prospectus supplement. Closing of the notes offering is expected on March 9, 2026, subject to customary conditions.
Abbott plans to use the net proceeds, together with cash on hand and/or additional borrowings, to fund consideration for its proposed acquisition of Exact Sciences Corporation, repay certain Exact Sciences indebtedness, cover related fees and expenses, and for general corporate purposes, which may include repayment of other debt.
Abbott Laboratories is offering $20,000,000,000 of notes across eight series to help fund its proposed acquisition of Exact Sciences. The offering includes eight series with aggregate principal amounts by series (Floating Rate and seven Fixed Rate maturities) and net proceeds estimated at $19,825,943,100. The notes will be unsecured, unsubordinated obligations ranking equally with Abbott’s other unsecured debt. Abbott intends to use proceeds, together with cash on hand or borrowings, to fund the Exact Sciences Acquisition, repay certain Exact Sciences indebtedness, pay related fees and expenses, and for general corporate purposes. If the Exact Sciences Acquisition is not consummated by the End Date or Abbott elects not to pursue it, Abbott must redeem outstanding notes at 101% plus accrued interest under a Special Mandatory Redemption provision.
Abbott Laboratories is offering multiple series of unsecured notes, including a floating-rate series tied initially to Compounded SOFR, and several fixed-rate series. The company intends to use net proceeds, together with cash on hand or borrowings, to fund the proposed acquisition of Exact Sciences for $105.00 per Exact Sciences share.
The prospectus supplement imposes a Special Mandatory Redemption if the Exact Sciences acquisition is not consummated by the date that is five business days after February 17, 2027 (or any later End Date agreed by the parties), requiring redemption at 101% of principal plus accrued interest. The notes will be unsecured and rank equally with Abbott’s other unsecured and unsubordinated debt.
Abbott Laboratories registers securities on a shelf prospectus under Form S-3, permitting the sale of debt securities, common shares, preferred shares, depositary shares, warrants, purchase contracts and units.
The prospectus is dated February 23, 2026 and states offerings may occur "From time to time after the effective date of this Registration Statement." As context, Abbott reports 1,737,682,887 common shares outstanding as of January 31, 2026 and 2,400,000,000 authorized common shares.
Abbott Laboratories is updating its corporate governance by changing the size of its Board of Directors. Effective April 24, 2026, the board will be reduced from thirteen directors to twelve, as reflected in an amendment to Article III, Section 2 of Abbott’s By-Laws.
The company has restated its By-Laws to incorporate this change, and the amended and restated By-Laws will be effective on the same date. No financial results or major transactions are included in this report; it focuses solely on this board size adjustment.
Abbott Laboratories files its annual report outlining 2025 performance and a planned acquisition of Exact Sciences. Abbott agreed to buy Exact Sciences for $105 per share in cash, valuing the equity at about $21 billion and the enterprise at roughly $23 billion, backed by a $20 billion bridge facility.
Growth was led by Medical Devices and Established Pharmaceuticals, with Medical Devices driven by diabetes care and structural heart products, while COVID‑19 testing revenue continued to decline. Operating margin improved to 18.2%, supported by margin initiatives despite inflation and foreign exchange headwinds.
Abbott ended 2025 with $8.9 billion in cash and short-term investments and $12.9 billion in long-term debt, and paid dividends of $2.40 per share, then raised the quarterly payout to $0.63. It repurchased 2.34 million shares in October 2025, leaving about $6.69 billion authorized. The filing details extensive risk factors and ongoing infant formula litigation and investigations but states management does not expect a material adverse financial impact.
Abbott Laboratories director Daniel J. Starks reported purchasing additional common shares of the company. On February 4, 2026, he bought 4,967 common shares at a weighted average price of $109.1388 and 5,033 common shares at a weighted average price of $108.3328.
Following these transactions, Starks beneficially owns 6,738,817 Abbott common shares directly. He also reports 258 common shares held indirectly through the Alynne Starks 2012 Irrevocable Trust, for which he serves as sole trustee.
Abbott Laboratories insider activity centers on a trust-related share transaction. The Ford Family Trust, for which Chairman and CEO Robert B. Ford serves as co-trustee, reported a transaction involving 18,800 Abbott common shares on January 23, 2026 at a weighted average price of $107.1259 per share, executed in multiple trades between $106.735 and $107.485. After this activity, the trust held 216,203 Abbott shares indirectly attributed to Ford, while a separate line shows 253,305 Abbott shares held directly in his name.